NCT01453049View on ClinicalTrials.gov

An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

rosiglitazone/glimepiride fix dose combination

oral, once daily, dosage is titrated according to FPG and hypoglycemia events

DRUG

glimepiride

oral, once daily, dosage is titrated according to FPG and hypoglycemia

Trial Locations (12)

100029

GSK Investigational Site, Beijing

100730

GSK Investigational Site, Beijing

110003

GSK Investigational Site, Shenyang

116027

GSK Investigational Site, Dalian

200080

GSK Investigational Site, Shanghai

215004

GSK Investigational Site, Suzhou

300052

GSK Investigational Site, Tianjin

310003

GSK Investigational Site, Hangzhou

310009

GSK Investigational Site, Hangzhou

400016

GSK Investigational Site, Chongqing

430022

GSK Investigational Site, Wuhan

430030

GSK Investigational Site, Wuhan

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01453049 - An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients | Biotech Hunter | Biotech Hunter